Comparison of Evidence-Based Versus Non-Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease

American Journal of Cardiology

Volumn 105, Issue 6, 2010, Pages 786-791

  Nichols, Gregory A ^a   Wang, Fang ^b   Pedula, Kathryn L ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE REGISTRY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EVIDENCE-BASED PRACTICE; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLATELET AGGREGATION INHIBITORS;

EID: 77649187915     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.11.008     Document Type: Article

References (23)

1. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., and Taubert K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
2. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., Pfeffer M.A., Rice M.M., Rosenberg Y.D., Rouleau J.L., and PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
3. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
4. Kastelein J.J.P., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt M., Demicco D.A., Szarek M., LaRosa J.C., Pedersen T.R., Grundy S.M., and TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
5. Lee H.Y., Cooke C.E., and Robertson T.A. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 14 (2008) 271-280
6. Austin P.C., Mamdani M.M., Juurlink D.N., Alter D.A., and Tu J.V. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. Am Heart J 151 (2006) 969-975
7. Doyle F., De La Harpe D., McGee H., Shelley E., and Conroy R. Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions. Eur J Cardiovasc Prev Rehabil 12 (2005) 376-379
8. Birkhead J.S., Weston C., and Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-2005: observational study. BMJ 332 (2006) 1306-1311
9. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50 (1997) 105-116
10. Manjunath M., Sarnak M., and Levey A. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 10 (2001) 785-792
11. Stokes M.E., Davis C.S., and Koch G.G. Categorical Data Analysis Using the SAS System (2000), SAS Institute, Cary: North Carolina
12. Steg P.G., Bhatt D.L., Wilson P.W.F., D'Agostino Sr. R., Ohman E.M., Rother J., Liau C.S., Hirsch A.T., Mas J.L., Ikeda Y., Pencina M.J., Goto S., and REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
13. Mahoney E.M., Wang K., Cohen D.J., Hirsch A.T., Alberts M.J., Eagle K., Mosse F., Jackson J.D., Steg G., Bhatt D.L., and REACH Registry Investigators. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 1 (2008) 38-45
14. Eagle K.A., Montoye C.K., Riba A.L., DeFranco A.C., Parrish R., Skorcz S., Baker P.L., Faul J., Jani S.M., Chen B., Roychoudhury C., Elma M.A.C., Mitchell K.R., and Mehta R.H. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 46 (2005) 1242-1248
15. Mukherjee D., Eagle K.A., Kline-Rogers E., Feldman L.J., Juliard J.M., Agnelli G., Budaj A., Avezum A., Allegrone J., FitzGerald G., Steg P.G., and GRACE Investigators. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol 100 (2007) 1-6
16. Mukherjee D., Fang J., Chetcuti S., Moscucci M., Kline-Rogers E., and Eagle K.A. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004) 745-749
17. Fonarow G.C., Gawlinski A., Moughrabi S., and Tillisch J.H. Improved Treatment of Coronary Heart Disease by Implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-922
18. Lim E., Brown A., Helmy A., Mussa S., and Altman D.G. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med 149 (2008) 612-617
19. Blackburn D.F., Dobson R.T., Blackburn J.L., Wilson T.W., Stang M.R., and Semchuk W.M. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 21 (2005) 485-488
20. Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., and Schwartz S. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165 (2005) 1147-1152
21. Kramer J.M., Hammill B., Anstrom K.J., Fetteroff D., Snyder R., Charde J.P., Hoffman B.S., LaPointe N.A., and Peterson E. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 152 (2006) 454.e1-454.e8
22. Kahn R., Robertson R.M., Smith R., and Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 118 (2008) 576-585
23. Robinson J.G., and Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 95 (2005) 373-378